Schultz: Businesses need to do more to help people
Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
| Previous Close | 0.60 |
| Open | 0.60 |
| Bid | 0.58 x 400 |
| Ask | 0.63 x 2600 |
| Day's Range | 0.58 - 0.60 |
| 52 Week Range | 0.38 - 1.14 |
| Volume | 139,505 |
| Avg. Volume | 418,753 |
| Market Cap | 40.94M |
| Beta | 0.61 |
| PE Ratio (TTM) | -2.90 |
| EPS (TTM) | -0.21 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- PR Newswire•4 days ago
Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial
ENGLEWOOD, Colo., Sept. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the completion of enrollment and dosing of patients in their pivotal single injection study on the "unmet medical need" of severe osteoarthritis of the knee (OAK). These patients experience not only pain but also the loss of function and diminished quality of life. The primary endpoint of this pivotal trial follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) OMERACT-OARSI responder rate to address the signs and symptoms of severe OAK. Michael Macaluso, Ampio's CEO, noted, "Announcing the close of enrollment so quickly speaks to the unmet medical need.
- PR Newswire•14 days ago
Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting
ENGLEWOOD, Colo. , Sept. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...
- PR Newswire•15 days ago
Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
ENGLEWOOD, Colo. , Sept. 7, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...
